ArticleMolecules (Basel, Switzerland)2018
Natural Scaffolds with Multi-Target Activity for the Potential Treatment of Alzheimer's Disease.
Article in Molecules (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 37 citations in OpenAlex.
- A Review on Phytochemical Constituents used as Current Treatment Strategies for Neurodegenerative Disease.Anti-inflammatory & anti-allergy agents in medicinal chemistry · 2025Review
- In Vitro Antioxidant and Antibacterial Activities of Ethyl Acetate Extracts ofMicroorganisms · 2024Article
- Targeting Biometals in Alzheimer's Disease with Metal Chelating Agents Including Coumarin Derivatives.CNS drugs · 2024Review
- Green Methods to Recover Bioactive Compounds from Food Industry Waste: A Sustainable Practice from the Perspective of the Circular Economy.Molecules (Basel, Switzerland) · 2024Review
- Naturally Occurring Cholinesterase Inhibitors from Plants, Fungi, Algae, and Animals: A Review of the Most Effective Inhibitors Reported in 2012-2022.Current neuropharmacology · 2024Review
- Historic recurrences in medicinal chemistry: nature-inspired structures as a new opportunity for novel multi-target anti-Alzheimer's drugs.Neural regeneration research · 2023Article
- Tenuazonic acid alters immune and physiological reactions and susceptibility to pathogens in Galleria mellonella larvae.Mycotoxin research · 2023Article
- Antimicrobial Natural Products from Plant Pathogenic Fungi.Molecules (Basel, Switzerland) · 2023Article
- Novel Phenothiazine/Donepezil-like Hybrids Endowed with Antioxidant Activity for a Multi-Target Approach to the Therapy of Alzheimer's Disease.Antioxidants (Basel, Switzerland) · 2022Article
- Butenolide derivatives fromFrontiers in chemistry · 2022Article
- Entomotoxic Activity of the Extracts from the Fungus,Journal of fungi (Basel, Switzerland) · 2021Article
- Derivatives of Tenuazonic Acid as Potential New Multi-Target Anti-Alzheimer's Disease Agents.Biomolecules · 2021Article
- Natural Compounds for the Prevention and Treatment of Cardiovascular and Neurodegenerative Diseases.Foods (Basel, Switzerland) · 2020Review
- Novel Perspective on Alzheimer's Disease Treatment: Rosmarinic Acid Molecular Interplay with Copper(II) and Amyloid β.Life (Basel, Switzerland) · 2020Article
- Deep Eutectic Solvents as Effective Reaction Media for the Synthesis of 2-Hydroxyphenylbenzimidazole-based Scaffolds en Route to Donepezil-Like Compounds.Molecules (Basel, Switzerland) · 2020Article
- Combining fatty acid amide hydrolase (FAAH) inhibition with peroxisome proliferator-activated receptor (PPAR) activation: a new potential multi-target therapeutic strategy for the treatment of Alzheimer's disease.Neural regeneration research · 2020Article
- Current and emerging therapeutic targets of alzheimer's disease for the design of multi-target directed ligands.MedChemComm · 2019Review
- Anti-Neuroinflammatory Property of Phlorotannins fromMarine drugs · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A few symptomatic drugs are currently available for Alzheimer's Disease (AD) therapy, but these molecules are only able to temporary improve the cognitive capacity of the patients if administered in the first stages of the pathology. Recently, important advances have been achieved about the knowledge of this complex condition, which is now considered a multi-factorial disease. Researchers are, thus, more oriented toward the preparation of molecules being able to contemporaneously act on different pathological features. To date, the inhibition of acetylcholinesterase (AChE) and of β-amyloid (Aβ) aggregation as well as the antioxidant activity and the removal and/or redistribution of metal ions at the level of the nervous system are the most common investigated targets for the treatment of AD. Since many natural compounds show multiple biological properties, a series of secondary metabolites of plants or fungi with suitable structural characteristics have been selected and assayed in order to evaluate their potential role in the preparation of multi-target agents. Out of six compounds evaluated,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.